Not yet taking people in Norvégia2. fázis
OmaMig Pilot
Key facts
- Where
- Oslo, NorvégiaSee the site
- Phase
- 2. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Norvégia
- Oslo Universitetssykehus HFOslo, NorvégiaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oslo University Hospital HF
- Trial code
- EU 2025-522448-41-00
- Record updated
- 2026. március 31.
- Original description
Evaluate the potential clinical benefit on monthly migraine days.Read full original descriptionShow less
OmaMig Pilot: An open-label, phase IIa, single arm pilot study evaluating the potential clinical benefit and safety of omalizumab in adults with episodic migraine.
Evaluate the potential clinical benefit on monthly migraine days.
Inclusion: Adults with episodic migraine and 4–14 migraine days pr month with or without aura according to the International Classification of Headache Disorders (ICHD-3).
Exclusion: Having tried ≥ 3 prophylactic drugs against migraine during the last 10 years; Use of other migraine preventives during the study; Interval headache not distinguishable from migraine; Breastfeeding or pregnancy.